Reports Q4 revenue $70.162M, consensus $67.19M. “In the last 5 years, Immunocore has transformed from a research organization to a revenue-generating, sustainable company,” said Bahija Jallal, CEO of Immunocore. “We look forward to the next 5 years, when we maximize the potential of KIMMTRAK, expect to launch our PRAME ImmTAC therapy, and advance our clinical candidates across oncology, infectious diseases and autoimmune diseases.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMCR:
- Immunocore enters trial collaboration, supply agreement with Bristol Myers
- Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
- Immunocore price target raised to $86 from $72 at Mizuho
- Immunocore Holdings Announces Offering Pricing Details
- Immunocore Holdings Establishes New Financial Obligation
